Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jul;38(7):1534–1540. doi: 10.1128/aac.38.7.1534

Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.

M A Jacobson 1, J Gallant 1, L H Wang 1, D Coakley 1, S Weller 1, D Gary 1, L Squires 1, M L Smiley 1, M R Blum 1, J Feinberg 1
PMCID: PMC284589  PMID: 7979285

Abstract

Valaciclovir, the L-valyl ester of acyclovir, is rapidly and extensively converted in humans to acyclovir after oral administration by first-pass metabolism. A phase I study was conducted in two cohorts of volunteers with advanced human immunodeficiency virus (HIV) disease (absolute CD4 lymphocyte count of < 150 cells per microliters) who received oral valaciclovir at dosages of 1,000 or 2,000 mg four times daily for 30 days. All patients were clinically stable without any changes in underlying HIV-related medications for > or = 6 weeks prior to entry in study; these medications were continued throughout the study. Multiple-dose administration of valaciclovir showed a generally favorable safety profile. Nausea, vomiting, diarrhea, and abdominal pain each were reported in < or = 31% of the patients; of these symptoms, only one episode of diarrhea was considered causally related to valaciclovir exposure. Four patients developed neutropenia (two at each dose level) which was not clinically significant. There were no renal or neurologic adverse events. Valaciclovir was rapidly absorbed and converted to acyclovir, with plasma valaciclovir levels generally undetectable or levels of < or = 0.4 microgram/ml. After 3 h postdosing, valaciclovir was not detectable in plasma. Acyclovir was measurable in plasma as early as 15 min following valaciclovir dosing, and plasma concentrations of acyclovir greatly exceeded those of valaciclovir. The mean values for the maximum concentration of drug in plasma, time to maximum concentration of drug in plasma, area under the concentration-time curve from 0 h to infinity, and apparent half-life of acyclovir obtained after single- and multiple-dose valaciclovir administration in HIV-infected patients were similar to those reported in normal healthy volunteers. The time to maximum concentration in serum and half-life of acyclovir after valaciclovir administration were approximately 2 and 3 h, respectively, which were similar to those reported after oral administration of acyclovir itself. The mean trough and peak acyclovir concentrations and the daily area under the concentration-time curve acyclovir values at steady state were 2.5 and 8.4 micrograms/ml and 120 h micrograms/ml, respectively, after a dosage of 2,000 mg of valaciclovir four times daily. These values were approximately fivefold greater than those achieved with high dosages of oral acyclovir (800 mg, five times daily) and were not affected by continued use of medications necessary for management of advanced HIV disease. Thus, 2,000 mg of valaciclovir given orally four times daily should be evaluated for its potential efficacy in suppressing cytomegalovirus and other herpes group virus infections not optimally managed with current oral acyclovir therapy.

Full text

PDF
1534

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antony M. A., Brandt L. J., Klein R. S., Bernstein L. H. Infectious diarrhea in patients with AIDS. Dig Dis Sci. 1988 Sep;33(9):1141–1146. doi: 10.1007/BF01535791. [DOI] [PubMed] [Google Scholar]
  2. Balfour H. H., Jr, Chace B. A., Stapleton J. T., Simmons R. L., Fryd D. S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989 May 25;320(21):1381–1387. doi: 10.1056/NEJM198905253202105. [DOI] [PubMed] [Google Scholar]
  3. Blum M. R., Liao S. H., de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med. 1982 Jul 20;73(1A):186–192. doi: 10.1016/0002-9343(82)90088-2. [DOI] [PubMed] [Google Scholar]
  4. Collier A. C., Bozzette S., Coombs R. W., Causey D. M., Schoenfeld D. A., Spector S. A., Pettinelli C. B., Davies G., Richman D. D., Leedom J. M. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med. 1990 Oct 11;323(15):1015–1021. doi: 10.1056/NEJM199010113231502. [DOI] [PubMed] [Google Scholar]
  5. Cooper D. A., Pedersen C., Aiuti F., Vilde J. L., Ruhnke M., Pehrson P. O., Clumeck N., Farthing C., Lüthy R., Doherty R. R. The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group. AIDS. 1991 Aug;5(8):933–943. doi: 10.1097/00002030-199108000-00003. [DOI] [PubMed] [Google Scholar]
  6. Erlich K. S., Mills J., Chatis P., Mertz G. J., Busch D. F., Follansbee S. E., Grant R. M., Crumpacker C. S. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 2;320(5):293–296. doi: 10.1056/NEJM198902023200506. [DOI] [PubMed] [Google Scholar]
  7. Fletcher C. V., Englund J. A., Edelman C. K., Gross C. R., Dunn D. L., Balfour H. H., Jr Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother. 1991 May;35(5):938–943. doi: 10.1128/aac.35.5.938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gallant J. E., Moore R. D., Richman D. D., Keruly J., Chaisson R. E. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992 Dec;166(6):1223–1227. doi: 10.1093/infdis/166.6.1223. [DOI] [PubMed] [Google Scholar]
  9. Heise W., Mostertz P., Arasteh K., Skörde J., L'age M. Gastrointestinale Befunde bei der HIV-Infektion. Klinik, mikrobiologische Befunde und endoskopisches Erscheinungsbild. Dtsch Med Wochenschr. 1988 Oct 14;113(41):1588–1593. doi: 10.1055/s-2008-1067854. [DOI] [PubMed] [Google Scholar]
  10. Jabs D. A., Enger C., Bartlett J. G. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989 Jan;107(1):75–80. doi: 10.1001/archopht.1989.01070010077031. [DOI] [PubMed] [Google Scholar]
  11. Jacobson M. A., Berger T. G., Fikrig S., Becherer P., Moohr J. W., Stanat S. C., Biron K. K. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990 Feb 1;112(3):187–191. doi: 10.7326/0003-4819-112-3-187. [DOI] [PubMed] [Google Scholar]
  12. Jacobson M. A., O'Donnell J. J., Porteous D., Brodie H. R., Feigal D., Mills J. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Q J Med. 1988 Jun;67(254):473–486. [PubMed] [Google Scholar]
  13. Kinchington D., Galpin S., Jaroszewski J. W., Ghosh K., Subasinghe C., Cohen J. S. A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Antiviral Res. 1992 Jan;17(1):53–62. doi: 10.1016/0166-3542(92)90090-r. [DOI] [PubMed] [Google Scholar]
  14. Lane G. P., Lucas C. R., Smallwood R. A. The gastrointestinal and hepatic manifestations of the acquired immunodeficiency syndrome. Med J Aust. 1989 Feb 6;150(3):139–143. doi: 10.5694/j.1326-5377.1989.tb136393.x. [DOI] [PubMed] [Google Scholar]
  15. Laskin O. L., Longstreth J. A., Saral R., de Miranda P., Keeney R., Lietman P. S. Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. Antimicrob Agents Chemother. 1982 Mar;21(3):393–398. doi: 10.1128/aac.21.3.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McGuffin R. W., Shiota F. M., Meyers J. D. Lack of toxicity of acyclovir to granulocyte progenitor cells in vitro. Antimicrob Agents Chemother. 1980 Sep;18(3):471–473. doi: 10.1128/aac.18.3.471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Meyers J. D., Reed E. C., Shepp D. H., Thornquist M., Dandliker P. S., Vicary C. A., Flournoy N., Kirk L. E., Kersey J. H., Thomas E. D. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988 Jan 14;318(2):70–75. doi: 10.1056/NEJM198801143180202. [DOI] [PubMed] [Google Scholar]
  18. Pertel P., Hirschtick R., Phair J., Chmiel J., Poggensee L., Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992;5(11):1069–1074. [PubMed] [Google Scholar]
  19. Sha B. E., Benson C. A., Deutsch T. A., Urbanski P. A., Phair J. P., Kessler H. A. Suppression of cytomegalovirus retinitis in persons with AIDS with high-dose intravenous acyclovir. J Infect Dis. 1991 Oct;164(4):777–780. doi: 10.1093/infdis/164.4.777. [DOI] [PubMed] [Google Scholar]
  20. Weller S., Blum M. R., Doucette M., Burnette T., Cederberg D. M., de Miranda P., Smiley M. L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993 Dec;54(6):595–605. doi: 10.1038/clpt.1993.196. [DOI] [PubMed] [Google Scholar]
  21. Zon L. I., Arkin C., Groopman J. E. Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol. 1987 Jun;66(2):251–256. doi: 10.1111/j.1365-2141.1987.tb01307.x. [DOI] [PubMed] [Google Scholar]
  22. de Miranda P., Blum M. R. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):29–37. doi: 10.1093/jac/12.suppl_b.29. [DOI] [PubMed] [Google Scholar]
  23. de Miranda P., Whitley R. J., Blum M. R., Keeney R. E., Barton N., Cocchetto D. M., Good S., Hemstreet G. P., 3rd, Kirk L. E., Page D. A. Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther. 1979 Dec;26(6):718–728. doi: 10.1002/cpt1979266718. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES